For research use only. Not for therapeutic Use.
APG-1387 (Cat.No:I022312), also known as SM-1387, is a IAP inhibitor. APG-1387 promotes the rapid degradation of cIAP1/2 and XIAP, and it exerts an antitumor effect on nasopharyngeal carcinoma cancer stem cells. Further studies show that APG-1387 enhances the chemosensitivity and promotes apoptosis in combination with CDDP and 5-FU of NPC in vitro and vivo.
Catalog Number | I022312 |
CAS Number | 1570231-89-8 |
Synonyms | APG-1387, APG 1387l; APG1387; SM-1387; SM 1387; SM1387. |
Molecular Formula | C60H72N10O10S2 |
Purity | ≥95% |
Target | IAP |
Solubility | Soluble in DMSO, not in water |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
IUPAC Name | (5S,5'S,8S,8'S,10aR,10a'R)-3,3'-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) |
InChI | InChI=1S/C60H72N10O10S2/c1-39(61-3)55(71)63-49-37-67(34-32-45-28-30-51(69(45)59(49)75)57(73)65-53(41-18-9-5-10-19-41)42-20-11-6-12-21-42)81(77,78)47-26-17-27-48(36-47)82(79,80)68-35-33-46-29-31-52(70(46)60(76)50(38-68)64-56(72)40(2)62-4)58(74)66-54(43-22-13-7-14-23-43)44-24-15-8-16-25-44/h5-27,36,39-40,45-46,49-54,61-62H,28-35,37-38H2,1-4H3,(H,63,71)(H,64,72)(H,65,73)(H,66,74)/t39-,40-,45+,46+,49-,50-,51-,52-/m0/s1 |
InChIKey | AKLBERUGKZNEJY-RTEPGWBGSA-N |
SMILES | O=C(NC(C1=CC=CC=C1)C2=CC=CC=C2)[C@@H]3CC[C@H](CCN(S(C4=CC=CC(S(N(C[C@@H]5NC([C@H](C)NC)=O)CC[C@@H]6N([C@H](C(NC(C7=CC=CC=C7)C8=CC=CC=C8)=O)CC6)C5=O)(=O)=O)=C4)(=O)=O)C[C@@H]9NC([C@@H](NC)C)=O)N3C9=O |
Reference | 1: Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K, Masiejczyk M, Wróbel A, Dolata I, Kitlińska A, Statkiewicz M, Kuklinska U, Goryca K, Sapała Ł, Grochowska A, Cabaj A, Szajewska-Skuta M, Gabor-Worwa E, Kucwaj K, Białas A, Radzimierski A, Combik M, Woyciechowski J, Mikulski M, Windak R, Ostrowski J, Brzózka K. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017 May 16;8(20):33779-33795. doi: 10.18632/oncotarget.16810. PubMed PMID: 28422713; PubMed Central PMCID: PMC5464911. |